
---
title: '失败的临床试验中蕴藏科学突破'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202205/07/154659migmggigpgpi25q1.jpg'
author: 科学网
comments: false
date: Sat, 07 May 2022 15:50:00 GMT
thumbnail: 'https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202205/07/154659migmggigpgpi25q1.jpg'
---

<div>   
<p style="line-height: 2em;"><span style="font-family: "times new roman"; font-size: 24px;">失败的临床试验导致科学突破：研究癌症药物毒性导致重大发现</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">诸平</span></p><p style="text-align: center;"><a href="https://scitechdaily.com/images/T-Cells-Attacking-Cancer-Cells.jpg" target="_self"><img src="https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202205/07/154659migmggigpgpi25q1.jpg" title alt="T-Cells-Attacking-Cancer-Cells-777x402.webp.jpg" referrerpolicy="no-referrer"></a><br></p><p style="line-height: 2em; text-align: center;"><a href="https://scitechdaily.com/failed-clinical-trial-leads-to-scientific-breakthrough-investigating-cancer-drug-toxicity-leads-to-critical-discovery/" style="font-size: 18px; font-family: "times new roman";" target="_blank">3D rendition of T cells attacking cancer cells. Credit: La Jolla Institute for Immunology</a><br></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">据美国拉霍亚免疫学研究所（</span><a href="https://wikijp.org/wiki/La_Jolla_Institute_for_Allergy_and_Immunology" style="font-size: 18px; font-family: "times new roman";" target="_blank">La Jolla Institute For Immunology</a><span style="font-size: 18px; font-family: "times new roman";">简称</span><a href="https://www.lji.org/" style="font-size: 18px; font-family: "times new roman";" target="_blank">LJI</a><span style="font-size: 18px; font-family: "times new roman";">)22<span style="font-family: 宋体;">年</span>5<span style="font-family: 宋体;">月</span>4<span style="font-family: 宋体;">日报道，失败的临床试验导致科学突破：研究癌症药物毒性导致重大发现（</span></span><a href="https://scitechdaily.com/failed-clinical-trial-leads-to-scientific-breakthrough-investigating-cancer-drug-toxicity-leads-to-critical-discovery/" style="font-size: 18px; font-family: "times new roman";" target="_blank">Failed Clinical Trial Leads to Scientific Breakthrough: Investigating Cancer Drug Toxicity Leads to Critical Discovery</a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-family: 宋体;">）。研究人员发现了一种避免癌症免疫疗法副作用的新策略。上述由拉霍亚免疫学研究所提供的图片，是攻击癌细胞的</span>T<span style="font-family: 宋体;">细胞的</span>3D<span style="font-family: 宋体;">再现。</span></span><br></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">失败的临床试验通常不会导致科学突破。但是，</span><span style="font-size: 18px; font-family: "times new roman";">当英国的患者在癌症免疫治疗试验期间开始出现负面副作用时，拉霍亚免疫学研究所（</span><a href="https://www.lji.org/" style="font-size: 18px; font-family: "times new roman";" target="_blank">LJI</a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-family: 宋体;">）癌症免疫治疗中心（</span>Center for Cancer Immunotherapy<span style="font-family: 宋体;">）和英国利物浦大学（</span>University of Liverpool<span style="font-family: 宋体;">）的研究人员回过头来检查数据，并与患者样本合作以确定究竟错在何处。他们的研究结果于</span>2022<span style="font-family: 宋体;">年</span>5<span style="font-family: 宋体;">月</span>4<span style="font-family: 宋体;">日已经在《自然》（</span></span><a href="https://www.nature.com/articles/s41586-022-04685-2" style="font-size: 18px; font-family: "times new roman";" target="_blank">Nature</a><span style="font-size: 18px; font-family: "times new roman";">）杂志网站发表——</span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Simon-Eschweiler" style="font-size: 18px; font-family: "times new roman";" target="_blank">Simon Eschweiler</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Ciro-Ram_rez_Su_stegui" style="font-size: 18px; font-family: "times new roman";" target="_blank">Ciro Ramírez-Suástegui</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Yingcong-Li" style="font-size: 18px; font-family: "times new roman";" target="_blank">Yingcong Li</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Emma-King" style="font-size: 18px; font-family: "times new roman";" target="_blank">Emma King</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Lindsey-Chudley" style="font-size: 18px; font-family: "times new roman";" target="_blank">Lindsey Chudley</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Jaya-Thomas" style="font-size: 18px; font-family: "times new roman";" target="_blank">Jaya Thomas</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Oliver-Wood" style="font-size: 18px; font-family: "times new roman";" target="_blank">Oliver Wood</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Adrian-Witzleben" style="font-size: 18px; font-family: "times new roman";" target="_blank">Adrian von Witzleben</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Danielle-Jeffrey" style="font-size: 18px; font-family: "times new roman";" target="_blank">Danielle Jeffrey</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Katy-McCann" style="font-size: 18px; font-family: "times new roman";" target="_blank">Katy McCann</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Hayley-Simon" style="font-size: 18px; font-family: "times new roman";" target="_blank">Hayley Simon</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Monalisa-Mondal" style="font-size: 18px; font-family: "times new roman";" target="_blank">Monalisa Mondal</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Alice-Wang" style="font-size: 18px; font-family: "times new roman";" target="_blank">Alice Wang</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Martina-Dicker" style="font-size: 18px; font-family: "times new roman";" target="_blank">Martina Dicker</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Elena-Lopez_Guadamillas" style="font-size: 18px; font-family: "times new roman";" target="_blank">Elena Lopez-Guadamillas</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Ting_Fang-Chou" style="font-size: 18px; font-family: "times new roman";" target="_blank">Ting-Fang Chou</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Nicola_A_-Dobbs" style="font-size: 18px; font-family: "times new roman";" target="_blank">Nicola A. Dobbs</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Louisa-Essame" style="font-size: 18px; font-family: "times new roman";" target="_blank">Louisa Essame</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Gary-Acton" style="font-size: 18px; font-family: "times new roman";" target="_blank">Gary Acton</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Fiona-Kelly" style="font-size: 18px; font-family: "times new roman";" target="_blank">Fiona Kelly</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Gavin-Halbert" style="font-size: 18px; font-family: "times new roman";" target="_blank">Gavin Halbert</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Joseph_J_-Sacco" style="font-size: 18px; font-family: "times new roman";" target="_blank">Joseph J. Sacco</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Andrew_Graeme-Schache" style="font-size: 18px; font-family: "times new roman";" target="_blank">Andrew Graeme Schache</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Richard-Shaw" style="font-size: 18px; font-family: "times new roman";" target="_blank">Richard Shaw</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-James_Anthony-McCaul" style="font-size: 18px; font-family: "times new roman";" target="_blank">James Anthony McCaul</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Claire-Paterson" style="font-size: 18px; font-family: "times new roman";" target="_blank">Claire Paterson</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Joseph_H_-Davies" style="font-size: 18px; font-family: "times new roman";" target="_blank">Joseph H. Davies</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Peter_A_-Brennan" style="font-size: 18px; font-family: "times new roman";" target="_blank">Peter A. Brennan</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Rabindra_P_-Singh" style="font-size: 18px; font-family: "times new roman";" target="_blank">Rabindra P. Singh</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Paul_M_-Loadman" style="font-size: 18px; font-family: "times new roman";" target="_blank">Paul M. Loadman</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-William-Wilson" style="font-size: 18px; font-family: "times new roman";" target="_blank">William Wilson</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Allan-Hackshaw" style="font-size: 18px; font-family: "times new roman";" target="_blank">Allan Hackshaw</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Gregory-Seumois" style="font-size: 18px; font-family: "times new roman";" target="_blank">Gregory Seumois</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Klaus-Okkenhaug" style="font-size: 18px; font-family: "times new roman";" target="_blank">Klaus Okkenhaug</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Gareth_J_-Thomas" style="font-size: 18px; font-family: "times new roman";" target="_blank">Gareth J. Thomas</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Terry_M_-Jones" style="font-size: 18px; font-family: "times new roman";" target="_blank">Terry M. Jones</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Ferhat-Ay" style="font-size: 18px; font-family: "times new roman";" target="_blank">Ferhat Ay</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Greg-Friberg" style="font-size: 18px; font-family: "times new roman";" target="_blank">Greg Friberg</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Mitchell-Kronenberg" style="font-size: 18px; font-family: "times new roman";" target="_blank">Mitchell Kronenberg</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Bart-Vanhaesebroeck" style="font-size: 18px; font-family: "times new roman";" target="_blank">Bart Vanhaesebroeck</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Pandurangan-Vijayanand" style="font-size: 18px; font-family: "times new roman";" target="_blank">Pandurangan Vijayanand</a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.nature.com/articles/s41586-022-04685-2#auth-Christian_H_-Ottensmeier" style="font-size: 18px; font-family: "times new roman";" target="_blank">Christian H. Ottensmeier</a><span style="font-size: 18px; font-family: "times new roman";">. Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs. </span><a href="https://www.nature.com/" style="font-size: 18px; font-family: "times new roman";" target="_blank">Nature</a><span style="font-size: 18px; font-family: "times new roman";">,  </span><a href="https://www.nature.com/articles/s41586-022-04685-2#article-info" style="font-size: 18px; font-family: "times new roman";" target="_blank">Published: 04 May 2022</a><span style="font-size: 18px; font-family: "times new roman";">. </span><a href="https://doi.org/10.1038/s41586-022-04685-2" style="font-size: 18px; font-family: "times new roman";" target="_blank">DOI: 10.1038/s41586-022-04685-2</a><span style="font-size: 18px; font-family: "times new roman";">. </span><a href="https://www.nature.com/articles/s41586-022-04685-2" style="font-size: 18px; font-family: "times new roman";" target="_blank">https://www.nature.com/articles/s41586-022-04685-2</a>. <span style="font-family: "times new roman"; font-size: 18px;">此文为为什么许多免疫疗法会引发危险的副作用提供了关键线索，并指出了治疗实体瘤患者的更有效策略。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">参与此项研究的除了来自美国</span><a href="https://www.lji.org/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">LJI</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">和英国利物浦大学的研究人员之外，还有来自美国加州大学圣地亚哥分校（</span>University of California San Diego, USA<span style="font-size: 18px; font-family: 宋体;">）、英国南安普敦大学（</span>University of Southampton, UK<span style="font-size: 18px; font-family: 宋体;">）、英国国民保健服务基金会普尔医院信托基金（</span>Poole Hospital NHS Foundation Trust, Poole, UK<span style="font-size: 18px; font-family: 宋体;">）、德国乌尔姆大学医学中心（</span>Ulm University Medical Center, Germany<span style="font-size: 18px; font-family: 宋体;">）、英国伦敦大学学院（</span>University College London, UK<span style="font-size: 18px; font-family: 宋体;">）、英国癌症研究所（</span>Cancer Research UK, London, UK<span style="font-size: 18px; font-family: 宋体;">）、英国斯特拉斯克莱德大学（</span>University of Strathclyde, Glasgow, UK<span style="font-size: 18px; font-family: 宋体;">）、利物浦大学医院</span>NHS<span style="font-size: 18px; font-family: 宋体;">基金会信托（</span>Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK<span style="font-size: 18px; font-family: 宋体;">）、英国格拉斯哥伊丽莎白女王大学医院（</span>Queen Elizabeth University Hospital, Glasgow, UK<span style="font-size: 18px; font-family: 宋体;">）、英国格拉斯哥比特森西苏格兰癌症中心（</span>Beatson West of Scotland Cancer Centre, Glasgow, UK<span style="font-size: 18px; font-family: 宋体;">）、英国朴次茅斯亚历山德拉皇后医院（</span>Queen Alexandra Hospital, Portsmouth, UK<span style="font-size: 18px; font-family: 宋体;">）、英国南安普顿大学医院</span>NHS<span style="font-size: 18px; font-family: 宋体;">基金会信托（</span>Southampton University Hospitals NHS Foundation Trust, Southampton, UK<span style="font-size: 18px; font-family: 宋体;">）、英国布拉德福德大学（</span>University of Bradford, UK<span style="font-size: 18px; font-family: 宋体;">）、英国癌症研究中心和伦敦大学学院癌症试验中心（</span>Cancer Research UK and UCL Cancer Trials Centre, London, UK<span style="font-size: 18px; font-family: 宋体;">）、英国剑桥大学（</span>University of Cambridge, UK<span style="font-size: 18px; font-family: 宋体;">）以及美国安进公司（</span>Amgen, Thousand Oaks, CA, USA<span style="font-size: 18px; font-family: 宋体;">）的研究人员。</span></span></p><p style="line-height: 2em;"><a href="https://www.lji.org/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">LJI</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">教授、医学博士</span>Pandurangan Vijayanand<span style="font-size: 18px; font-family: 宋体;">说：</span>“<span style="font-size: 18px; font-family: 宋体;">这项工作表明了从早期临床试验中学习的重要性。</span>”Pandurangan Vijayanand<span style="font-size: 18px; font-family: 宋体;">与医学博士、皇家内科医师学会会员（</span>Fellow of the Royal College of Physicians<span style="font-size: 18px; font-family: 宋体;">简称</span>FRCP<span style="font-size: 18px; font-family: 宋体;">）、利物浦大学教授、克拉特布里奇癌症中心</span> NHS <span style="font-size: 18px; font-family: 宋体;">基金会信托基金教授、</span></span><a href="https://www.lji.org/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">LJI</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">兼职教授</span>Christian H. Ottensmeier<span style="font-size: 18px; font-family: 宋体;">共同领导了这项新研究。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong><span style="font-size: 18px; font-family: 宋体;">免疫疗法的成功有限（</span></strong><strong><span style="font-size: 18px; font-family: 宋体;"></span></strong><strong><a href="https://scitechdaily.com/failed-clinical-trial-leads-to-scientific-breakthrough-investigating-cancer-drug-toxicity-leads-to-critical-discovery/" target="_blank">Limited success with immunotherapies</a></strong><strong><span style="font-size: 18px; font-family: 宋体;">）</span></strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">Pandurangan Vijayanand<span style="font-size: 18px; font-family: 宋体;">和</span>Christian H. Ottensmeier<span style="font-size: 18px; font-family: 宋体;">都是医学科学家，</span>Christian H. Ottensmeier<span style="font-size: 18px; font-family: 宋体;">是治疗实体瘤患者的主治肿瘤学家。在过去的十年里，由于免疫疗法的进步，他看到越来越多的患者茁壮成长，得益于免疫疗法与免疫系统一起杀死癌症。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">Christian H. Ottensmeier<span style="font-size: 18px; font-family: 宋体;">说：</span>“<span style="font-size: 18px; font-family: 宋体;">在肿瘤学领域，免疫疗法彻底改变了我们对治疗的看法。即使患有转移性和传播性疾病，我们也可以为患者提供免疫疗法，然后仅仅三年后就挥手告别并告诉他们他们的癌症已经治愈。这是一个惊人的变化。</span>”</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">不幸的是，只有大约</span>20%<span style="font-size: 18px; font-family: 宋体;">到</span>30%<span style="font-size: 18px; font-family: 宋体;">的接受免疫疗法的实体癌患者进入长期缓解状态。有些人在免疫治疗后看不到任何变化，但有些人在治疗期间肺部、肠道甚至皮肤出现严重问题。这些副作用可能使人衰弱，甚至致命，这些患者被迫停止接受免疫治疗。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong><span style="font-size: 18px; font-family: 宋体;">临床试验的重要教训（</span></strong><strong><span style="font-size: 18px; font-family: 宋体;"></span></strong><strong><a href="https://scitechdaily.com/failed-clinical-trial-leads-to-scientific-breakthrough-investigating-cancer-drug-toxicity-leads-to-critical-discovery/" target="_blank">Important lessons from a clinical trial</a></strong><strong><span style="font-size: 18px; font-family: 宋体;">）</span></strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">LJI<span style="font-size: 18px; font-family: 宋体;">和利物浦大学的研究人员使用了英国最近一项针对头颈癌</span>(head and neck cancers)<span style="font-size: 18px; font-family: 宋体;">患者的临床试验的样本。这些患者接受了一种称为</span> PI3Kd <span style="font-size: 18px; font-family: 宋体;">抑制剂</span>(PI3Kd inhibitor)<span style="font-size: 18px; font-family: 宋体;">的口腔癌免疫疗法。当时，</span>PI3Kd<span style="font-size: 18px; font-family: 宋体;">抑制剂已被证明对</span>B<span style="font-size: 18px; font-family: 宋体;">细胞淋巴瘤（</span>B cell lymphomas<span style="font-size: 18px; font-family: 宋体;">）有效，但尚未在实体瘤中进行测试。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">PI3Kd <span style="font-size: 18px; font-family: 宋体;">抑制剂是癌症免疫治疗领域的新产品，但它们有望抑制</span>“<span style="font-size: 18px; font-family: 宋体;">调节性</span>”T<span style="font-size: 18px; font-family: 宋体;">细胞</span> (“regulatory” T cells<span style="font-size: 18px; font-family: 宋体;">简称</span>Tregs)<span style="font-size: 18px; font-family: 宋体;">。</span>Tregs<span style="font-size: 18px; font-family: 宋体;">通常会试图阻止其他</span>T<span style="font-size: 18px; font-family: 宋体;">细胞也称为效应</span>T<span style="font-size: 18px; font-family: 宋体;">细胞（</span>effector T cells<span style="font-size: 18px; font-family: 宋体;">）靶向人体自身的组织。肿瘤学家抑制肿瘤内的</span>Treg<span style="font-size: 18px; font-family: 宋体;">，因此效应</span>T <span style="font-size: 18px; font-family: 宋体;">细胞可以释放并产生杀死癌症的</span> CD8+ T<span style="font-size: 18px; font-family: 宋体;">细胞。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"> “<span style="font-size: 18px; font-family: 宋体;">拥有一种可以解除</span>Tregs<span style="font-size: 18px; font-family: 宋体;">作用的口服片剂，对于肿瘤学家来说可能是一笔巨大的财富，</span>”Pandurangan Vijayanand<span style="font-size: 18px; font-family: 宋体;">说。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">不幸的是，试验中的</span> 21 <span style="font-size: 18px; font-family: 宋体;">名患者中有</span> 12 <span style="font-size: 18px; font-family: 宋体;">名不得不提前停止治疗，因为他们在结肠中出现炎症，这种情况称为结肠炎（</span>colitis<span style="font-size: 18px; font-family: 宋体;">）。</span>“<span style="font-size: 18px; font-family: 宋体;">我们认为这种药物不会有毒，那为什么会这样呢？</span>” Pandurangan Vijayanand<span style="font-size: 18px; font-family: 宋体;">说。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">LJI <span style="font-size: 18px; font-family: 宋体;">讲师西蒙·埃施韦勒（</span>Simon Eschweiler<span style="font-size: 18px; font-family: 宋体;">）博士带头回溯并确切了解</span> PI3Kd <span style="font-size: 18px; font-family: 宋体;">抑制剂治疗如何影响这些患者的免疫细胞。使用单细胞基因组测序，他发现在增加肿瘤中抗肿瘤</span>T<span style="font-size: 18px; font-family: 宋体;">细胞的过程中，</span>PI3Kd<span style="font-size: 18px; font-family: 宋体;">抑制剂还阻止了特定的</span>Treg<span style="font-size: 18px; font-family: 宋体;">细胞亚群保护结肠。如果没有</span>Tregs<span style="font-size: 18px; font-family: 宋体;">发挥作用，称为</span>Th17<span style="font-size: 18px; font-family: 宋体;">和</span>Tc17<span style="font-size: 18px; font-family: 宋体;">细胞的致病性</span>T<span style="font-size: 18px; font-family: 宋体;">细胞就会进入并引起炎症和结肠炎。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">很明显，癌症试验患者接受的</span> PI3Kd <span style="font-size: 18px; font-family: 宋体;">抑制剂剂量超过了他们所需的剂量，而免疫疗法使肠道中免疫细胞的微妙组成失去了平衡。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">西蒙·埃施韦勒说，导致新研究中发现的毒性的途径可能广泛适用于其他具有类似</span>Treg<span style="font-size: 18px; font-family: 宋体;">细胞的器官，以及其他靶向</span>Treg<span style="font-size: 18px; font-family: 宋体;">细胞的免疫疗法，如抗</span>CTLA-4<span style="font-size: 18px; font-family: 宋体;">。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong><span style="font-size: 18px; font-family: 宋体;">新的给药策略可以挽救生命（</span></strong><strong><span style="font-size: 18px; font-family: 宋体;"></span></strong><strong><a href="https://scitechdaily.com/failed-clinical-trial-leads-to-scientific-breakthrough-investigating-cancer-drug-toxicity-leads-to-critical-discovery/" target="_blank">New dosing strategy may save lives</a></strong><strong><span style="font-size: 18px; font-family: 宋体;">）</span></strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">研究小组发现，间歇给药可能是一种有效的治疗策略，将持续的抗肿瘤免疫与降低的毒性相结合。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">研究人员现在正在设计一项人体临床试验，以测试人体的间歇给药策略。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">LJI <span style="font-size: 18px; font-family: 宋体;">教授兼首席科学官米切尔·克罗嫩贝格（</span>Mitchell Kronenberg<span style="font-size: 18px; font-family: 宋体;">）博士说：</span>“<span style="font-size: 18px; font-family: 宋体;">这项研究说明了如何从临床研究转到小鼠研究，以了解这些患者的毒性背后的原因。</span>”<span style="font-size: 18px; font-family: 宋体;">对于此项新研究来说，是米切尔·克罗嫩贝格的实验室领导了大部分小鼠模型工作。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">如何解释</span>B<span style="font-size: 18px; font-family: 宋体;">细胞淋巴瘤（</span>B cell lymphomas<span style="font-size: 18px; font-family: 宋体;">）试验中缺乏毒性？西蒙·埃施韦勒说，先前研究中的淋巴瘤患者已经接受了几种先前的治疗，导致整体免疫功能低下。这意味着淋巴瘤患者对</span> PI3Kd <span style="font-size: 18px; font-family: 宋体;">抑制没有相同类型或相同程度的免疫反应。同时，头颈癌患者未接受过治疗。他们的免疫系统没有受到损害，因此与免疫相关的不良事件更快也更明显。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">总体而言，这项新研究显示了不仅要研究个性化治疗，还要研究个性化治疗剂量和时间表的重要性。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">正如</span>Christian H. Ottensmeier<span style="font-size: 18px; font-family: 宋体;">解释的那样，十年前医生只能提供一种免疫疗法。它要么帮助了病人，要么没有。今天的医生有一个快速增长的免疫疗法库可供选择。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">Pandurangan Vijayanand<span style="font-size: 18px; font-family: 宋体;">和</span>Christian H. Ottensmeier<span style="font-size: 18px; font-family: 宋体;">是首批使用单细胞基因组测序工具来确定哪些治疗组合对个体患者最有效的研究人员之一，以及提供这些治疗的最佳时间表。在</span>2021 <span style="font-size: 18px; font-family: 宋体;">年</span></span><a href="https://www.lji.org/news-events/news/post/many-cancer-patients-may-need-a-sequential-one-two-punch-of-immunotherapies/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Nature Immunology</span></a><a href="https://www.lji.org/news-events/news/post/many-cancer-patients-may-need-a-sequential-one-two-punch-of-immunotherapies/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">的一项研究</span></a><span style="font-size: 18px; font-family: "times new roman";">（</span><a href="https://www.lji.org/news-events/news/post/many-cancer-patients-may-need-a-sequential-one-two-punch-of-immunotherapies/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Nature Immunology</span></a><a href="https://www.lji.org/news-events/news/post/many-cancer-patients-may-need-a-sequential-one-two-punch-of-immunotherapies/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";"> study</span></a><span style="font-size: 18px; font-family: "times new roman";">）中，两人展示了以特定顺序进行免疫疗法的潜在重要性。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">Pandurangan Vijayanand<span style="font-size: 18px; font-family: 宋体;">说：</span>“<span style="font-size: 18px; font-family: 宋体;">如果你设计好你的临床试验并应用复杂的基因组学，你就有很多东西要学。你可以弄清楚发生了什么，然后再回到病人身边。</span>”</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">如果没有一支高技能的国际合作者团队，他们的使命是不可能完成的。</span>Christian H. Ottensmeier<span style="font-size: 18px; font-family: 宋体;">说：</span>“<span style="font-size: 18px; font-family: 宋体;">这项研究是一项非凡的合作努力的结果。这需要一群医学肿瘤学家、外科医生、研究护士、我们的病人以及科学家</span>——<span style="font-size: 18px; font-family: 宋体;">他们都在围绕患者一起协同工作。</span>”</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">这项研究得到了</span> CDD <span style="font-size: 18px; font-family: 宋体;">试验拨款</span> (CDD trial Grant CRUKD/15/004; CI: CHO)<span style="font-size: 18px; font-family: 宋体;">、英国癌症研究中心网络加速器奖拨款</span> (Cancer Research UK Centres Network Accelerator Award Grant: A21998)<span style="font-size: 18px; font-family: 宋体;">、英国癌症研究中心（</span>CRUK<span style="font-size: 18px; font-family: 宋体;">）和</span>NIHR<span style="font-size: 18px; font-family: 宋体;">实验癌症医学中心</span> (Experimental Cancer Medicine Center<span style="font-size: 18px; font-family: 宋体;">简称</span>ECMC) <span style="font-size: 18px; font-family: 宋体;">南安普顿</span> (CRUK and NIHR Experimental Cancer Medicine Center (ECMC) Southampton: A15581)<span style="font-size: 18px; font-family: 宋体;">、</span>CRUK<span style="font-size: 18px; font-family: 宋体;">和</span> NIHR ECMC<span style="font-size: 18px; font-family: 宋体;">利物浦</span> (CRUK and NIHR ECMC Liverpool: A25153)<span style="font-size: 18px; font-family: 宋体;">、英国癌症研究计划资助</span>(Cancer Research UK Programme Grant: C23338/A25722)<span style="font-size: 18px; font-family: 宋体;">；英国</span> NIHR UCLH <span style="font-size: 18px; font-family: 宋体;">生物医学研究中心（</span>UK NIHR UCLH Biomedical Research Centre<span style="font-size: 18px; font-family: 宋体;">），</span>S10OD025052<span style="font-size: 18px; font-family: 宋体;">（</span>Illumina Novaseq6000<span style="font-size: 18px; font-family: 宋体;">），</span>S10RR027366<span style="font-size: 18px; font-family: 宋体;">（</span>FACSAria II cell sorter<span style="font-size: 18px; font-family: 宋体;">）；</span>NIH <span style="font-size: 18px; font-family: 宋体;">赠款</span> P01 DK46763<span style="font-size: 18px; font-family: 宋体;">（</span>NIH grant P01 DK46763<span style="font-size: 18px; font-family: 宋体;">）、威廉·鲍斯基金会（</span>William K. Bowes Jr Foundation<span style="font-size: 18px; font-family: 宋体;">）和惠塔克·</span> <span style="font-size: 18px; font-family: 宋体;">艾楚雷基金会（</span>Whittaker iCure Foundation<span style="font-size: 18px; font-family: 宋体;">）、德国研究基金会</span>DFG<span style="font-size: 18px; font-family: 宋体;">研究奖学金（</span>Deutsche Forschungsgemeinschaft DFG research fellowship # WI 5255/1-1:1<span style="font-size: 18px; font-family: 宋体;">）、欧文薛定谔奖学金（</span>Erwin Schrödinger Fellowship: M.D.<span style="font-size: 18px; font-family: 宋体;">）的支持。这项工作的临床交付得到了威塞克斯临床研究网络（</span>Wessex Clinical Research Network<span style="font-size: 18px; font-family: 宋体;">）和英国国立卫生研究院（</span>National Institute of Health Research UK<span style="font-size: 18px; font-family: 宋体;">）的支持。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">上述介绍，仅供参考。欲了解更多信息，敬请注意浏览</span><a href="https://www.nature.com/articles/s41586-022-04685-2" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">原文</span></a><span style="font-size: 18px; font-family: "times new roman";">或者</span><a href="https://scitechdaily.com/failed-clinical-trial-leads-to-scientific-breakthrough-investigating-cancer-drug-toxicity-leads-to-critical-discovery/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">相关报道</span></a><span style="font-size: 18px; font-family: "times new roman";">。</span></p><p style="line-height: 2em;"><a href="https://www.nature.com/articles/s41586-022-04685-2" style="text-decoration: underline; font-size: 18px; font-family: "arial black", "avant garde";" target="_blank"><span style="font-size: 18px; font-family: "arial black", "avant garde";">Abstract</span></a></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">Phosphoinositide 3-kinase δ (PI3Kδ) has a key role in lymphocytes, and inhibitors that target this PI3K have been approved for treatment of B cell malignancies<sup><a href="https://www.nature.com/articles/s41586-022-04685-2#ref-CR1" title="Furman, R. R. et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 370, 997–1007 (2014)." target="_blank">1</a>,<a href="https://www.nature.com/articles/s41586-022-04685-2#ref-CR2" title="Gopal, A. K. et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N. Engl. J. Med. 370, 997–1007 (2014)." target="_blank">2</a>,<a href="https://www.nature.com/articles/s41586-022-04685-2#ref-CR3" title="Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., André, F. & Okkenhaug, K. PI3K inhibitors are finally coming of age. Nat. Rev. Drug Discov. 20, 741–769 (2021)." target="_blank">3</a></sup>. Although studies in mouse models of solid tumours have demonstrated that PI3Kδ inhibitors (PI3Kδi) can induce anti-tumour immunity<sup><a href="https://www.nature.com/articles/s41586-022-04685-2#ref-CR4" title="Ali, K. et al. Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 510, 407–411 (2014)." target="_blank">4</a>,<a href="https://www.nature.com/articles/s41586-022-04685-2#ref-CR5" title="Lim, E. L. et al. Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors. JCI Insight 3, e120626 (2018)." target="_blank">5</a></sup>, its effect on solid tumours in humans remains unclear. Here we assessed the effects of the PI3Kδi AMG319 in human patients with head and neck cancer in a neoadjuvant, double-blind, placebo-controlled randomized phase II trial (EudraCT no. 2014-004388-20). PI3Kδ inhibition decreased the number of tumour-infiltrating regulatory T (T<sub>reg</sub>) cells and enhanced the cytotoxic potential of tumour-infiltrating T cells. At the tested doses of AMG319, immune-related adverse events (irAEs) required treatment to be discontinued in 12 out of 21 of patients treated with AMG319, suggestive of systemic effects on T<sub>reg</sub> cells. Accordingly, in mouse models, PI3Kδi decreased the number of T<sub>reg</sub> cells systemically and caused colitis. Single-cell RNA-sequencing analysis revealed a PI3Kδi-driven loss of tissue-resident colonic ST2 Treg cells, accompanied by expansion of pathogenic T helper 17 (T<sub>H</sub>17) and type 17 CD8+ T (T<sub>C</sub>17) cells, which probably contributed to toxicity; this points towards a specific mode of action for the emergence of irAEs. A modified treatment regimen with intermittent dosing of PI3Kδi in mouse models led to a significant decrease in tumour growth without inducing pathogenic T cells in colonic tissue, indicating that alternative dosing regimens might limit toxicity.</span></p><p><br></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自诸平科学网博客。<br>链接地址：</label><a href="https://blog.sciencenet.cn/blog-212210-1337463.html" target="_blank" style="font-size:13px; color:#850f0f">https://blog.sciencenet.cn/blog-212210-1337463.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-212210-1337192.html" target="_black">解开植物病毒为何如此强大的抗癌之谜</a><br>                    <!--大赛结束-->
                                        
  
</div>
            